Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1

Interventions

liposomal amphotericin B 2hypericin 2Vorinostat 2Psychiatric Rehabilitation 2Peripheral Blood Stem Cell Transplantation 2Levofloxacin 2Early Intervention, Educational 2Darbepoetin alfa 2Brentuximab Vedotin 2zanolimumab 1mogamulizumab 1ferrous sulfate 1ferric gluconate 1Vancomycin 1Valacyclovir 1Therapeutics 1Tazobactam 1Sucrose 1Ribavirin 1Radiotherapy 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Phototherapy 1Pharmacogenomic Testing 1Palivizumab 1Ondansetron 1Moxifloxacin 1Morphine 1Methotrexate 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell, Cutaneous × zanolimumab × Clear all
NCT00127881 2012-07-26

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Emergent Product Development Seattle LLC

Phase 3 Terminated
76 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡